

EMEA



# Vaccines and substances of ruminant origin

## The EU viewpoint

Roland Dötschler, Dr. Sc.

CPMP Biotechnology Working Party

EMEA - London

*Answers*

## Vaccines: examples

*Type of vaccine*  
*Bacterial cells (live or  
inactivated)*

- Live Oral Typhoid vaccine
- Inactivated Whole Cell Pertussis vaccine

*Examples*

- Live Oral Typhoid vaccine
- Inactivated Whole Cell Pertussis vaccine
- Diphtheria and Tetanus toxoids
- Acellular Pertussis Antigens
- rDNA Hepatitis B vaccine
- Haemophilus b vaccine
- Live attenuated Measles, Mumps, Rubella vaccines
- Inactivated Poliomyelitis vaccine (IPV)


*Purified bacterial cell  
products*

*Live and purified inactivated  
viral vaccines produced on  
mammalian cells*






# Bacterial Vaccines: production process



Substances of ruminant origin may be used



# Viral Vaccines: production process



Substances of ruminant origin may be used



## Vaccines: residual quantities of substances of ruminant origin

- Bacterial vaccines:
  - <100 ng (<0.1 µg)/single human dose when used in fermentation
- Viral vaccines:
  - <50 ng (<0.05 µg)/single human dose from use in production cell culture
  - <0.01 nL (<0.00001 µL)/single human dose from use in cell bank



## Vaccines and substances of ruminant origin

- Milk and milk derivatives (bacterial seeds and fermentation medium)
- Blood and blood derivatives (bacterial seeds and fermentation medium; calf serum in production of virus seed lots, cell banks, production cells)
- Gelatin derivatives (bacterial seeds)
- Tallow derivatives (glycerol as stabiliser in bacterial seeds and Tween 80 as emulsifier in viral vaccine production)
- Meat and organ extracts (bacterial fermentation)




## Vaccines and substances of ruminant origin Conclusions

- Substances of ruminant origin are used
- Vaccine safety ensured by the combination of
  - Control of origin (country/herd/animal)
  - Tissue of origin (no infectivity demonstrated)
  - Production stage at which used (generally initial stages)
  - Treatment (e.g. gelatin, Tween 80)



## Vaccines are not associated with vCJD

vCJD by year of birth



Adapted from P D Minor, R G Will, D Salisbury 2000, Vaccine, in press

